Sign in

    Myriam Belghiti

    Research Analyst at LifeSci Capital

    Myriam Belghiti is an Equity Research Analyst at LifeSci Capital, specializing in biotech and neuroscience sectors. She has provided research coverage on companies such as Corbus Pharmaceuticals and has achieved a 66.7% success rate in her investment recommendations, earning a 2.37-star ranking on TipRanks. Myriam joined LifeSci Capital as an Equity Research Associate in mid-2020, following prior internships and research roles at Cresilon, NYU Langone Medical Center, and Columbia University. She holds a Master's in Biomedical Engineering and a Bachelor's in Neuroscience and Behavior from Columbia University, and is affiliated with FINRA-member organizations.

    Myriam Belghiti's questions to SOLENO THERAPEUTICS (SLNO) leadership

    Myriam Belghiti's questions to SOLENO THERAPEUTICS (SLNO) leadership • Q1 2025

    Question

    Myriam Belghiti inquired about the potential impact of evolving international tariff policies on Soleno's business operations and launch activities.

    Answer

    CFO James MacKaness stated that the company does not anticipate any significant impact from current tariff policies. CEO Anish Bhatnagar elaborated that this is because both the drug substance and drug product are manufactured in the U.S., minimizing exposure to international trade tariffs.

    Ask Fintool Equity Research AI

    Myriam Belghiti's questions to SOLENO THERAPEUTICS (SLNO) leadership • Q1 2025

    Question

    Myriam Belghiti inquired about the potential impact of evolving international tariff policies on Soleno's business operations and launch.

    Answer

    Executive James MacKaness stated that the company does not foresee any significant impact from current tariff policies. Executive Anish Bhatnagar elaborated that this is because both the drug substance and drug product are manufactured by U.S.-based vendors.

    Ask Fintool Equity Research AI

    Myriam Belghiti's questions to AVADEL PHARMACEUTICALS (AVDL) leadership

    Myriam Belghiti's questions to AVADEL PHARMACEUTICALS (AVDL) leadership • Q1 2025

    Question

    Myriam Belghiti of LifeSci Capital asked for clarification on the recent Federal Circuit court decision, specifically what it means for the case to be remanded to the District Court and whether an injunction is still a possibility.

    Answer

    CEO Gregory Divis explained that the Federal Circuit vacated the injunction against seeking FDA approval because the District Court's original reasoning was deemed 'too speculative.' He stated that while the issue was sent back for reconsideration, the vacature provides Avadel with a clear and immediate pathway to file for and seek FDA approval for new indications like IH, which he described as a very important win for the company.

    Ask Fintool Equity Research AI

    Myriam Belghiti's questions to AVADEL PHARMACEUTICALS (AVDL) leadership • Q4 2024

    Question

    Myriam Belghiti of LifeSci Capital asked about Avadel's strategy for converting physicians who are new to prescribing oxybates into regular LUMRYZ prescribers. She also inquired if the company has an ideal patient mix goal for 2025 between switch and new-to-oxybate patients.

    Answer

    Executive Gregory Divis highlighted that over 200 physicians who had never prescribed an oxybate have now prescribed LUMRYZ, demonstrating market expansion. The expanded sales force is now targeting more physicians with similar profiles. Executive Thomas McHugh clarified that while Avadel has internal targets, the primary goal is to drive overall demand and improve all key metrics, rather than focusing on a single patient mix ratio, to ultimately grow revenue.

    Ask Fintool Equity Research AI